an-automated-radiosynthesis-of-68gaga-fapi-46-for-routine-clinical-use

An Automated Radiosynthesis of [<sup>68</sup>Ga]Ga-FAPI-46 for Routine Clinical Use

[68Ga]Ga-FAPI-46 is a promising new tracer for the imaging of fibroblast activation protein (FAP) by positron emission tomography (PET). Labeled FAP ...

Sir Charles Gairdner Hospital

Since first becoming commercially available in 2018, the PET radiopharmaceutical [ F]PSMA-1007 has been used widely for the diagnosis and staging of prostate cancer. A pharmacopoeia monograph first became available in 2021, prescribing a radiochemical purity specification of >91%, based on analytical results from both TLC (for [ F]fluoride impurity alone) and HPLC (for all other  F-impurities). Though this monograph has provided clarity for the quality control testing of [ F]PSMA-1007, it prescribes a HPLC method using phosphate buffer mobile phase that may present a risk of precipitation of phosphate salts in the HPLC system. The method also requires specialised hardware not immediately available to all laboratories. This work describes the development of a simple, rapid reversed-phase HPLC method utilising 0.1 M ammonium formate mobile phase for the accurate assessment of both [ F]fluoride impurity and overall radiochemical purity in a single test. This method is especially useful for assessment of product stability over time. A more accurate TLC method for [ F]fluoride impurity is also described.

Development of a high-performance liquid chromatography method for rapid radiochemical purity measurement of [ F]PSMA-1007, a PET radiopharmaceutical for detection of prostate cancer.

Zr-labelled proteins are gaining importance in clinical research in a variety of diseases. To date, no clinical study has been reported that utilizes an automated approach for radiosynthesis of Zr-labelled radiopharmaceuticals. We aim to develop an automated method for the clinical production of Zr-labelled proteins and apply this method to Durvalumab, a monoclonal antibody targeting PD-L1 immune-checkpoint protein. PD-L1 expression is poorly understood and can be up-regulated over the course of chemo- and radiotherapy treatment. The ImmunoPET multicentre study aims to examine the dynamics of PD-L1 expression via Zr-Durvalumab PET imaging before, during, and after chemoradiotherapy. The developed automated technique will enable reproducible clinical production of [Zr]Zr-DFOSq-Durvalumab for this study at three different sites.

Article	Year
Development of a high-performance liquid chromatography method for rapid radiochemical purity measurement of [ F]PSMA-1007, a PET radiopharmaceutical for detection of prostate cancer. Journal of labelled compounds & radiopharmaceuticals\| PubMed ID: 36649714	2023
Automated radiosynthesis of [Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo. Nuclear medicine and biology\| PubMed ID: 37224789	2023

Shifaza Mohamed

Biography

JoVE Journal Publications

Other Publications